A “cast” instead of an implant
About 60 million people worldwide live with atrial fibrillation, and roughly 90% of the blood clots that cause AF-related strokes form inside the left atrial appendage. Existing closure devices are rigid metal implants; they can be hard to fit because each appendage has a different shape, can injure the heart wall with their anchoring barbs, and may not be fully covered by the patient’s own tissue, which in itself can become a source of clots.
Fuwai Hospital, the Chinese Academy of Medical Sciences’ national cardiovascular centre, reports that a team led by its vice-president Pan Xiangbin — in partnership with Professor Xu Tiantian’s group at the Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences — published a paper in Nature in March 2026 describing a different approach. Instead of inserting a fixed-shape device, the team injects a magnetic fluid through a catheter into the left atrial appendage. The fluid fills every nook of the pouch, is held in place by an external magnetic field while it solidifies, and then keeps its shape after the magnetic field is removed.
How the method is designed to work
According to the Fuwai account, the approach has three reported elements. First, because the material is fluid when injected, it can spread through the fine ridges and pockets of the appendage and produce what the team describes as an imaging-level “zero residual leak.” Second, an external magnetic field provides about six times the holding force needed to resist the shear stress of normal left atrial blood flow during the solidification step, which is intended to keep the material in place while it sets; the solidified plug then holds itself. Third, the fluid is doped with agents that make it visible under both X-ray and ultrasound, so the procedure can be performed in a standard catheterisation laboratory or in a more basic setting that only has an ultrasound machine.
The preclinical evidence
The Fuwai account describes post-procedure CT reconstructions and anatomical cross-sections showing no measurable gap between the solidified material and the wall of the appendage in the experimental animals, and reports a two-year follow-up with stable implantation in the long-term cohort. The hospital’s promotional material is broadly optimistic, but it does not, in the article we reviewed, give specific numbers for sample size, animal species, follow-up completeness, or how the result compares head-to-head with a standard metal occluder in the same model. The hospital has separately indicated that first-in-human trials of the magnetic-fluid approach are expected within one to two years.
The Nature paper is a preclinical research paper in large-animal models, not a clinical trial in patients. It does not establish safety or efficacy in humans, and the source article we reviewed does not report human cases. The encouraging imaging findings and the reported two-year stability in animals are early signals, not outcomes that can be transferred to patient care. The method also depends on the heart-team’s ability to perform the procedure under ultrasound rather than X-ray, which Fuwai’s PAN Procedure makes possible in selected centres but is not standard elsewhere.
What this may mean for patients
For people with atrial fibrillation today, the practical message is unchanged: left atrial appendage closure, when appropriate, is most often performed with approved metal or bioabsorbable devices, and the Fuwai magnetic-fluid method is a research programme, not a treatment option to ask for. The Nature publication does, however, point to a plausible next generation of closure technology in which the implant is shaped to the patient’s anatomy rather than chosen from a small range of device sizes, and in which the procedure can be done without radiation. International patients should treat this as background on where the field is moving, not as an indication that a magnetic-fluid closure is available at Fuwai for routine care.
Relevance to atrial fibrillation and stroke prevention
Stroke prevention in atrial fibrillation sits at the intersection of Wellward China’s Heart & Circulation and Brain & Nervous System health areas. This summary is about a research line, not about deciding any individual patient’s closure strategy.